Active immunotherapy for non-small-cell lung cancer: moving toward a reality

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Rosell R, Skrzypski M, Jassem E et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One2(11), e1129 (2007).
   PubMed Web of Science ®Google Scholar
• Sandler A, Yi J, Dahlberg S, Kolb MM et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carwboplatin for advanced non-small-cell lung cancer. J. Thorac. Oncol.5(9), 1416–1423 (2010).
   PubMed Web of Science ®Google Scholar
• Gross S, Walden P. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer? Immunol. Lett.116(1), 7–14 (2008).
   PubMed Web of Science ®Google Scholar
• Holt GE, Podack ER, Raez LE. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy8(1), 43–54 (2011).
   PubMedGoogle Scholar
• Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anti-cancer vaccination strategies. Exp. Biol. Med.232, 1130–1141 (2007).
   PubMed Web of Science ®Google Scholar
• Kasid A, Bell GI, Director EP. Effects of transforming growth factor-β on human lymphokine activated killer cell precursors: autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J. Immunol.141, 690–698 (1988).
   PubMed Web of Science ®Google Scholar
• Tsunawaki S, Sporn M, Ding A et al. Deactivation of macrophages by transforming growth factor-β. Nature334, 260–262 (1988).
   PubMed Web of Science ®Google Scholar
• Naganuma H, Sasaki A, Satoh E et al. Transforming growth factor-β inhibits interferon-γ secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol. Med. Chir.36, 789–795 (1996).
   PubMedGoogle Scholar
• Kong F, Jirtle RL, Huang DH et al. Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer86, 1712–1719 (1999).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor β-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol.24, 4721–4730 (2006).
   PubMed Web of Science ®Google Scholar
• Hayes DN, Monti S, Parmigiani G et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol.24(31), 5079–5090 (2006).
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA.98(24), 13790–13795 (2001).
   PubMed Web of Science ®Google Scholar
• Raez LE, Cassileth PA, Schlesselman JJ et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J. Clin. Oncol.22(14), 2800–2807 (2004).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Sterman D, Jablons D et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl Cancer Inst.96(4), 326–331 (2004).
   PubMed Web of Science ®Google Scholar
• Schreiber TH, Deyev VV, Rosenblatt JD, Podack ER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res.69(5), 2026–2033 (2009).
   PubMedGoogle Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100(14), 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T lymphocyte antigen. J. Clin. Oncol.23(25), 6043–6053 (2005).
   PubMed Web of Science ®Google Scholar
• Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin. Immunol.22(3), 105–112 (2010).
   PubMed Web of Science ®Google Scholar
• González G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum. Vaccin.3(1), 8–13 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Crombet T, Torres F et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann. Oncol.14(3), 461–466 (2003).
   PubMed Web of Science ®Google Scholar
• Ramos TC, Vinageras EN, Ferrer MC et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol. Ther.5(2), 145–149 (2006).
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood105(7), 2862–2868 (2005).
   PubMed Web of Science ®Google Scholar
• Neninger E, Verdecia BG, Crombet T et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother.32(1), 92–99 (2009).
   PubMed Web of Science ®Google Scholar
• Sienel W, Varwerk C, Linder A et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small-cell lung cancer: results of a multi-center study. Eur. J. Cardiothorac. Surg.25, 131–134 (2004).
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Altorki NK, Stockert E et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol.172(5), 3289–3296 (2004).
   PubMed Web of Science ®Google Scholar
• Murad YM, Clay TM, Lyerly HK, Morse MA. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin. Biol Ther.7(8), 1257–1266 (2007).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol.24(6), 693–701 (2004).
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Zielinski H, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small-cell lung cancer (NSCLC). J. Clin. Oncol.25(18S), 7554 (2007).
   Web of Science ®Google Scholar
• Raina D, Kosugi M, Ahmad R et al. Dependence on the MUC1-C oncoprotein in non-small-cell lung cancer cells. Mol. Cancer Ther.10(5), 806–816 (2011).
   PubMed Web of Science ®Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med.4, 43–49 (1998).
   PubMed Web of Science ®Google Scholar
• Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer3(1), 49–57 (2001).
   PubMedGoogle Scholar
• Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol.23(27), 6674–6681 (2005).
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med.5(8), 690–699 (2003).
   PubMed Web of Science ®Google Scholar
• Ramlau R, Quoix E, Rolski J et al. A Phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small-cell lung cancer. J. Thorac. Oncol.3(7), 735–744 (2008).
   PubMed Web of Science ®Google Scholar
• Acres B, Quoix E, Ramlau R et al. Biomarkers associated with clinical outcome in advanced non-small-cell lung cancer patients treated with TG4010. J. Clin. Oncol.27, 15s (2009) (Abstract 3027).
   Google Scholar